Daiichi Sankyo Company, Limited (FRA:D4S)

Market Cap	39.15B
Revenue (ttm)	11.40B
Net Income (ttm)	1.61B
Shares Out	n/a
EPS (ttm)	0.86
PE Ratio	24.29
Forward PE	n/a
Dividend	0.41 (1.94%)
Ex-Dividend Date	Sep 29, 2025

Volume	5,003
Average Volume	399
Open	20.86
Previous Close	21.02
Day's Range	20.85 - 20.86
52-Week Range	18.03 - 31.68
Beta	n/a
RSI	54.58
Earnings Date	Jan 30, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ...

• Industry: Pharmaceutical Preparations
• Founded: 1899
• Employees: 19,765
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: D4S

Financial Performance

In 2024, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.

Financial numbers in JPY